Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models

Cancer Letters

Volumn 317, Issue 1, 2012, Pages 16-23

  José, Anabel ^a,b   Sobrevals, Luciano ^a,b   Ivorra, Antoni ^c   Fillat, Cristina ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Bioluminescent imaging; Irreversible electroporation; Orthotopic pancreatic cancer xenografts; Pancreatic ductal adenocarcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; LUCIFERASE; TRIACYLGLYCEROL LIPASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; ELECTROPORATION; ENZYME ACTIVITY; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRREVERSIBLE ELECTROPORATION; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR NECROSIS; TUMOR XENOGRAFT;

ALANINE TRANSAMINASE; AMYLASES; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROCHEMOTHERAPY; FEASIBILITY STUDIES; GENES, REPORTER; HUMANS; LIPASE; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, NUDE; MICROVESSELS; NECROSIS; PANCREATIC NEOPLASMS; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 84856334722     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.004     Document Type: Article

References (25)

1. Kern S.E., Shi C., Hruban R.H. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J. Pathol. 2011, 223:295-306.
2. D'Onofrio M., Barbi E., Girelli R., Martone E., Gallotti A., Salvia R., Martini P.T., Bassi C., Pederzoli P., Pozzi Mucelli R. Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J. Gastroenterol. 2010, 16:3478-3483.
3. Harrison L.E., Koneru B., Baramipour P., Fisher A., Barone A., Wilson D., Dela Torre A., Cho K.C., Contractor D., Korogodsky M. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J. Am. Coll. Surg. 2003, 197:759-764.
4. Rhim H. Complications of radiofrequency ablation in hepatocellular carcinoma. Abdom. Imaging 2005, 30:409-418.
5. Breton M., Mir L.M. Microsecond and nanosecond electric pulses in cancer treatments. Bioelectromagnetics 2011, 1-18.
6. Mir L.M., Orlowski S., Belehradek J., Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur. J. Cancer 1991, 27:68-72.
7. Heller L.C., Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr. Gene. Ther. 2010, 10:312-317.
8. Cascante A., Huch M., Rodriguez L.G., Gonzalez J.R., Costantini L., Fillat C. Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo. Hum. Gene. Ther. 2005, 16:1377-1388.
9. Rubinsky B., Onik G., Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol. Cancer Res. Treat. 2007, 6:37-48.
10. Guo Y., Zhang Y., Klein R., Nijm G.M., Sahakian A.V., Omary R.A., Yang G.Y., Larson A.C. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res. 2010, 70:1555-1563.
11. Neal R.E., Davalos R.V. The feasibility of irreversible electroporation for the treatment of breast cancer and other heterogeneous systems. Ann. Biomed. Eng. 2009, 37:2615-2625.
12. Pech M., Janitzky A., Wendler J.J., Strang C., Blaschke S., Dudeck O., Ricke J., Liehr U.B. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Inter. Radiol. 2010, 34:132-138.
13. Garcia-Rodriguez L., Abate-Daga D., Rojas A., Gonzalez J.R., Fillat C. E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models. Gene. Ther. 2011, 18:73-81.
14. Kim M.P., Evans D.B., Wang H., Abbruzzese J.L., Fleming J.B., Gallick G.E. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc. 2009, 4:1670-1680.
15. Ivorra A., Al-Sakere B., Rubinsky B., Mir L.M. Use of conductive gels for electric field homogenization increases the antitumor efficacy of electroporation therapies. Phys. Med. Biol. 2008, 53:6605-6618.
16. Huch M., Abate-Daga D., Roig J.M., Gonzalez J.R., Fabregat J., Sosnowski B., Mazo A., Fillat C. Targeting the CYP2B 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models. Hum. Gene. Ther. 2006, 17:1187-1200.
17. Huch M., Gros A., Jose A., Gonzalez J.R., Alemany R., Fillat C. Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia 2009, 11:518-528. (514 p following 528).
18. Kim H., Morgan D.E., Buchsbaum D.J., Zeng H., Grizzle W.E., Warram J.M., Stockard C.R., McNally L.R., Long J.W., Sellers J.C., Forero A., Zinn K.R. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res. 2008, 68:8369-8376.
19. Lee C.J., Spalding A.C., Ben-Josef E., Wang L., Simeone D.M. In vivo bioluminescent imaging of irradiated orthotopic pancreatic cancer xenografts in nonobese diabetic-severe combined immunodeficient mice: a novel method for targeting and assaying efficacy of ionizing radiation. Transl. Oncol. 2010, 3:153-159.
20. McNally L.R., Welch D.R., Beck B.H., Stafford L.J., Long J.W., Sellers J.C., Huang Z.Q., Grizzle W.E., Stockard C.R., Nash K.T., Buchsbaum D.J. KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clin. Exp. Metastasis 2010, 27:591-600.
21. Bower M., Sherwood L., Li Y., Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J. Surg. Oncol. 2011.
22. Girelli R., Frigerio I., Salvia R., Barbi E., Tinazzi Martini P., Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br. J. Surg. 2010, 97:220-225.
23. Wu Y., Tang Z., Fang H., Gao S., Chen J., Wang Y., Yan H. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J. Surg. Oncol. 2006, 94:392-395.
24. Maor E., Ivorra A., Leor J., Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol. Cancer Res. Treat. 2007, 6:307-312.
25. Li W., Fan Q., Ji Z., Qiu X., Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One 2011, 6:e18831.